We have a number of newer hormone pathway drugs now available to treat men with metastatic castrate resistant prostate cancer (mCRPC). Researchers have shown that prostate specific antigen (PSA) response can be used as a pharmaco-dynamic end-point that may help identify men with early resistance to these new drugs. They found that there is clinical [...]
Many of the posts that I have written discussed the need for evaluating our current advanced prostate cancer drugs in both combinations and their sequencing. We have a number of new drugs, but we don’t understand how best to sequence them, or whether or not some drugs would do better and extend life by taking [...]
We have many new drugs to treat metastatic castrate resistant prostate cancer (mCRPC), but not all men have a positive result to each of the drug. Understanding who might obtain a positive result to a specific drug prior giving it will save both the individual man and society time and money. Understanding this it becomes [...]
There is more evidence that the blood test used to count the number of cells circulating in the blood and shed from prostate tumors (circulating tumor cells or CTCs) can indicate whether a treatment is working or not working. A major new study showed that the number of these circulating tumor cells in the blood [...]
When the FDA approved Abiraterone with prednisone (Zytiga) in the pre-chemotherapy stage they approved it after an interim analysis of data was performed of the phase III clinical trial (COU-AA-302), The analysis was performed by an independent data monitoring committee that found a significant difference in radiographic progression-free survival (scans that showed no tumor progression [...]